Peer Review HEMOGLOBIN LEVELS IN PULMONARY TUBERCULOSIS PATIENTS WHO CONSUMING ANTI-TUBERCULOSIS MEDICINE

Djami, Supriati Wila and Djuma, Agustina and Tangkelangi, Marni (2022) Peer Review HEMOGLOBIN LEVELS IN PULMONARY TUBERCULOSIS PATIENTS WHO CONSUMING ANTI-TUBERCULOSIS MEDICINE. Jurnal Ilmiah STIKES Kendal, 12 (04). ISSN e-ISSN 2549-8134; p-ISSN 2089-0834

Text PR Pen.Hb Tuberculosis Okt2022.pdf Download (2MB)

Abstract

Tuberculosis (TB) is a lung infection characterized by pulmonary infiltrates and the formation of caseous granulomas, fibrosis, and cavities. TB is the second leading cause of death from infectious diseases worldwide, after the human immunodeficiency virus (HIV). To reduce the death rate due to TB, the government carried out the Find Drugs Until Heal program with examinations for 6-9 months to kill the Mycobacterium tuberculosis bacteria with anti-tuberculosis drugs, namely Isoniazid, Rifampicin, Ethambutanol, Streptomycin, and Pyrazinamide. Anti Tuberculosis Drugs can cause fever, nausea and hematological reactions such as anemia, agranulocytosis, eosinophilia and thrombocytopenia. The research method used is descriptive using a cross sectional approach, namely to find out the description of hemoglobin levels in Tuberculosis patients who consume Anti Tuberculosis Drugs. 60%, in the productive age of 31-50 years with a percentage of 67% and occurs in patients with two months of treatment, namely initial or intensive treatment with a percentage of 87%.

Item Type:	Article
Uncontrolled Keywords:	Anti-tuberculosis drugs; Hemoglobin; Lungs; Mycobacterium Tuberculosis; Tuberculosis
Subjects:	R Medicine > R Medicine (General) R Medicine > RB Pathology
Divisions:	Jurusan Analis Kesehatan Jurusan Analis Kesehatan Jurusan Analis Kesehatan
Depositing User:	Mrs Supriati Wila Djami
Date Deposited:	30 Apr 2023 13:03
Last Modified:	30 Apr 2023 13:03
URI:	http://repository.poltekeskupang.ac.id/id/eprint/4132

Actions (login required)

View Item